Safety
Metvixia (methyl aminolevulinate) Cream, 16.8% For Topical Use Only
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- June 2008
| The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. |
| Sections Modified | Summary of Changes to Contraindications and Warnings |
|
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
DRUG INTERACTIONS USE IN SPECIFIC POPULATIONS
PATIENT PACKAGE INSERT (to include use with the Aktilite CL 128 lamp) |
WARNINGS AND PRECAUTIONS Photosensitivity During the time period between the application of Metvixia Cream and exposure to Aktilite red light illumination, the treatment site will become photosensitive. If for any reason the patient cannot have the Aktilite red light treatment after application of Metvixia Cream, the cream should be rinsed off, and the patient should protect the treated area from sunlight, prolonged or intense light for two days. Prolonged exposure for greater than 4 hours to Metvixia Cream should be avoided... Aktilite Lamp Before operating the Aktilite CL128 lamp, personnel should refer to the Operators Manual for specific warnings, cautions and instructions. Care should be exercised when positioning and operating the lamp. During the red light illumination period, the patient, operator and other persons present should wear protective goggles that sufficiently screen out the appropriate spectrum of red light. The protective goggles or eye shields provided for the patient are dark or of metal to block visible light... |







